SRR25617832
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.320
- MYC_TARGETS_V2+0.220
- KRAS_SIGNALING_DN+0.170
- MYOGENESIS+0.160
- ANGIOGENESIS+0.110
- APICAL_JUNCTION+0.080
- APICAL_SURFACE+0.070
- COAGULATION+0.060
- NOTCH_SIGNALING+0.060
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- INTERFERON_ALPHA_RESPONSE-0.390
- INFLAMMATORY_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- UV_RESPONSE_DN-0.370
- KRAS_SIGNALING_UP-0.350
- E2F_TARGETS-0.330
- IL2_STAT5_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.893 |
| 2 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.878 |
| 3 | AUR-AD9E-TTM4-A-1-1-R-A542-39 | — | B | 0.814 |
| 4 | TCGA-E2-A1BD-01A-11R-A12P-07 | — | B | 0.810 |
| 5 | SRR8613793 | — | B | 0.803 |
| 6 | R22 | — | — | 0.802 |
| 7 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.801 |
| 8 | AUR-AD9E-TTM2-A-1-1-R-A542-39 | — | B | 0.796 |
| 9 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.795 |
| 10 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |